| Name | cytochrome P450 (protein family or complex) |
|---|---|
| Synonyms | cytochrome P450; cytochrome P 450; CYP450; CYP 450 |
| Name | thiabendazole |
|---|---|
| CAS |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 3557233 | Ogata A, Yoneyama M, Sasaki M, Suzuki K, Imamichi T: Effects of pretreatment with SKF-525A or phenobarbital on thiabendazole-induced teratogenicity in ICR mice. Food Chem Toxicol. 1987 Feb;25(2):119-24. To study the effects of SKF-525A, an inhibitor of cytochrome P-450, and of phenobarbital (PB), a drug-metabolizing enzyme inducer, on the teratogenicity of thiabendazole (TBZ), pregnant mice were given ip either a single dose of 40 mg SKF-525A/kg 1 hr before oral dosing with 250 or 500 mg TBZ/kg or a dose of 75 mg PB/kg/day on three consecutive days before oral administration of a dose of 500 or 1000 mg TBZ/kg. |
81(1,1,1,1) | Details |
| 8607843 | Rey-Grobellet X, Ferre N, Eeckhoutte C, Larrieu G, Pineau T, Galtier P: Structural requirements for the induction of cytochromes P450 by benzimidazole anthelmintic derivatives in cultured rabbit hepatocytes. Biochem Biophys Res Commun. 1996 Mar 27;220(3):789-94. The effect of -containing benzimidazoles (thiabendazole, 5--thiabendazole, cambendazole) and -free derivatives (benzimidazole, carbendazim and 5-hydroxycarbendazim) on cytochrome P450 enzymes was investigated in primary cultures of rabbit hepatocytes considered 72 h after plating. |
81(1,1,1,1) | Details |
| 16261361 | Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM: Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol. 2005 Nov;61(10):755-61. Epub 2005 Oct 29. OBJECTIVE: To investigate the likelihood of artemisinin and thiabendazole causing pharmacokinetic interactions involving cytochrome P450 (CYP1A2) in humans given their potent inhibitory effects on the isoform in vitro. |
81(1,1,1,1) | Details |
| 8819304 | Rey-Grobellet X, Eeckhoutte C, Sutra JF, Alvinerie M, Galtier P: Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation. Xenobiotica. 1996 Jul;26(7):765-78. In order to characterize precisely the cytochrome P450 isozyme (s) involved in its major route of metabolism, a rapid and sensitive spectrofluorimetric method was developed for the simultaneous determination of thiabendazole and its main hepatic metabolite 5-hydroxythiabendazole. 2. |
31(0,1,1,1) | Details |
| 2433198 | Yoneyama M, Ichikawa H: Irreversible in vivo and in vitro binding of thiabendazole to tissue protein of pregnant mice. Food Chem Toxicol. 1986 Dec;24(12):1283-6. In experiments carried out in vitro, the binding of [14C] thiabendazole to microsomal protein of the liver was proportional to time and protein concentration, was dependent upon the presence of and and was inhibited by or SKF-525A, indicating that it was mediated by the cytochrome P-450-dependent monooxygenase system. |
31(0,1,1,1) | Details |
| 18570159 | Price RJ, Scott MP, Giddings AM, Walters DG, Stierum RH, Meredith C, Lake BG: Effect of butylated hydroxytoluene, propyl and thiabendazole on cytochrome P450 forms in cultured human hepatocytes. Xenobiotica. 2008 Jun;38(6):574-86. |
12(0,0,2,2) | Details |
| 12920490 | Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P (450) s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. Using the CL (H) predicted from the in vitro data, the compounds could be classified into three different categories: high-clearance drugs (> 70% liver blood flow; amodiaquine, praziquantel, albendazole, thiabendazole), low-clearance drugs (<30% liver blood flow; chloroquine, dapsone, diethylcarbamazine, pentamidine, primaquine, pyrantel, pyrimethamine, tinidazole) and intermediate clearance drugs (artemisinin, artesunate, quinine). |
3(0,0,0,3) | Details |
| 2344991 | Mizutani T, Ito K, Nomura H, Nakanishi K: Nephrotoxicity of thiabendazole in mice depleted of by treatment with DL-buthionine sulphoximine. Food Chem Toxicol. 1990 Mar;28(3):169-77. Treatment with three inhibitors of renal microsomal cytochrome P-450-dependent monooxygenases, piperonyl butoxide, methoxsalen and carbon disulphide, all equally prevented the nephrotoxicity of TBZ given in combination with BSO. |
1(0,0,0,1) | Details |
| 16669866 | Virkel G, Lifschitz A, Sallovitz J, Pis A, Lanusse C: Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. J Vet Pharmacol Ther. 2006 Jun;29(3):213-23. Conversely, thiabendazole (TBZ) and fenbendazole (FBZ) did not affect the oxidative metabolism of both incubated substrates. TCBZ sulphoxidative metabolism was also reduced (24% inhibition, P < 0.05) by the cytochrome P450 inhibitor piperonyl butoxide (PB). |
1(0,0,0,1) | Details |
| 10554308 | Coulet M, Eeckhoutte C, Larrieu G, Sutra JF, Hoogenboom LA, Huveneers-Oorsprong MB, Kuiper HA, Castell JV, Alvinerie M, Galtier P: Comparative Metabolism of Thiabendazole in Cultured Hepatocytes from Rats, Rabbits, Calves, Pigs, and Sheep, Including the Formation of Protein-Bound Residues. J Agric Food Chem. 1998 Feb 16;46(2):742-748. Moreover, the protein-bound residues in these cells, which could be related to cytochrome P450-dependent oxidation, were formed in 4 times greater amounts than in the other animal cells. |
1(0,0,0,1) | Details |
| 16714371 | Diani-Moore S, Papachristou F, Labitzke E, Rifkind AB: Induction of CYP1A and cyp2-mediated epoxygenation and suppression of by derivatives including the aromatase inhibitor vorozole. Drug Metab Dispos. 2006 Aug;34(8):1376-85. Epub 2006 May 19. Cytochrome P450 (P450) enzymes metabolize the membrane lipid to stable biologically active epoxides [eicosatrienoic acids (EETs)] and (20-HETE). We report here that derivative drugs: the anthelminthics, albendazole and thiabendazole; the proton pump inhibitor, the thromboxane synthase inhibitor, benzylimidazole; and the aromatase (CYP19) inhibitor vorozole (R76713, racemate; and R83842, (+) enantiomer) increased hepatic microsomal EET formation in a chick embryo model. |
1(0,0,0,1) | Details |
| 9565779 | Coulet M, Dacasto M, Eeckhoutte C, Larrieu G, Sutra JF, Alvinerie M, Mace K, Pfeifer AM, Galtier P: Identification of human and rabbit cytochromes P450 1A2 as major isoforms involved in thiabendazole 5-hydroxylation. Fundam Clin Pharmacol. 1998;12(2):225-35. This report characterized one of the major cytochrome P450 isozyme involved in thiabendazole metabolism. |
1(0,0,0,1) | Details |
| 1674242 | Upton RA: Pharmacokinetic interactions between and other medication (Part I). Clin Pharmacokinet. 1991 Jan;20(1):66-80. Many drugs have been found to increase or decrease the clearance of probably by interaction with one or more of the variants of the cytochrome P450 drug-metabolising system. Its clearance has been found to be decreased (typically by around 25%, but often by far more) by erythromycin, troleandomycin (triacetyloleandomycin), roxithromycin, enoxacin, ciprofloxacin, pefloxacin, norfloxacin, ofloxacin, fluoroquinolone T-3262, pipemidic acid, cimetidine, etintidine, nifedipine, at least some anovulent agents, viloxazine, allopurinol, ticlopidine, idrocilamide, thiabendazole, disulfiram, influenza- and BCG-vaccination, interferon, and (half-life increase). |
1(0,0,0,1) | Details |
| 7520238 | Aix L, Rey-Grobellet X, Larrieu G, Lesca P, Galtier P: Thiabendazole is an inducer of cytochrome P4501A1 in cultured rabbit hepatocytes. Biochem Biophys Res Commun. 1994 Aug 15;202(3):1483-9. At the highest concentrations and without apparent cellular toxicity, the drug provokes a dose-dependent increase in total microsomal cytochrome P450 and a rise in EROD activity which was correlated to a specific increase in P4501A1 level. |
1(0,0,0,1) | Details |
| 12408568 | Almli B, Egaas E, Christiansen A, Eklo OM, Lode O, Kallqvist T: Effects of three fungicides alone and in combination on glutathione S-transferase activity (GST) and cytochrome P-450 (CYP 1A1) in the liver and gill of brown trout (Salmo trutta). Mar Environ Res. 2002 Sep-Dec;54(3-5):237-40. Furthermore, continuous exposure to 540 ug/l thiabendazole [2-(thiazol-4'-yl) benzimidazole] in a flow-through system for 4 days significantly increased the gill glutathione S-transferase (GST) activity towards CDNB, whilst hepatic GST and cytochrome P450 (CYP 1A) activities were not increased by the treatment. |
1(0,0,0,1) | Details |
| 15110098 | Price RJ, Scott MP, Walters DG, Stierum RH, Groten JP, Meredith C, Lake BG: Effect of thiabendazole on some rat hepatic xenobiotic metabolising enzymes. Food Chem Toxicol. 2004 Jun;42(6):899-908. TB was found to be a mixed inducer of cytochrome P450 (CYP) forms in the CYP1A and CYP2B subfamilies. |
1(0,0,0,1) | Details |
| 2085232 | Kawalek JC, Fetterer RH: Effect of Haemonchus contortus infection on the clearance of antipyrine, sulfobromophthalein, chloramphenicol, and sulfathiazole in lambs. Am J Vet Res. 1990 Dec;51(12):2044-9. Second, infection of lambs by H contortus may have triggered an inductive response in hepatic cytochrome P-450-mediated activities, which might result via a generalized enhancement in hepatic protein synthesis associated with the physiologic response to replace plasma proteins and other blood components lost through gastrointestinal hemorrhage caused by the active feeding of adult worms. Clearance of antipyrine was enhanced by the infection, and thiabendazole treatment did not alter this effect. |
1(0,0,0,1) | Details |
| 1626124 | Mizutani T, Yoshida K, Ito K: Nephrotoxicity of thiazoles structurally related to thiabendazole in mice depleted of by treatment with buthionine sulfoximine. Res Commun Chem Pathol Pharmacol. 1992 Jan;75(1):29-38. |
0(0,0,0,0) | Details |
| 9784250 | Kikuchi H, Hossain A, Yoshida H, Kobayashi S: Induction of cytochrome P-450 1A1 by in human HepG2 cells is protein tyrosine kinase-dependent and is not inhibited by alpha-naphthoflavone. Arch Biochem Biophys. 1998 Oct 15;358(2):351-8. Benzimidazole compounds, such as and thiabendazole, are a different type of CYP1A1 inducer from Ah receptor-ligands, such as TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) and 3-methylcholanthrene. |
0(0,0,0,0) | Details |
| 494664 | Wilson CG, Parke DV, Green J, Cawthorne MA: Inhibition of thiabendazole metabolism in the rat. Xenobiotica. 1979 Jun;9(6):343-51. |
0(0,0,0,0) | Details |